Loss of control eating disorder in children age 12 years and younger: proposed research criteria
Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury
GLP-1 microdosing is suitable for: Individuals at risk for chronic diseases (cardiovascular, neurological, renal) Those pursuing longevity or preventive health measures Patients seeking sustainable wellness beyond weight loss Consultation with your doctor is required to confirm eligibility
At the molecular level, all three target receptors are Gs-coupled GPCRs that signal through cyclic AMP (cAMP) and protein kinase A (PKA), creating coordinated intracellular signaling that comprehensively shifts metabolism toward a catabolic state favoring fat oxidation and weight loss
Juan Manuel Perics has also received personal fees, mainly travel support, from Boehringer-Ingelheim, Madrigal, NovoNordisk, MSD and Novartis outside the submitted work
Our team recommends creating a simple rotation schedule
